Beneficial effect of antidepressants against rotenone induced Parkinsonism like symptoms in rats. Issue 2 (June 2016)
- Record Type:
- Journal Article
- Title:
- Beneficial effect of antidepressants against rotenone induced Parkinsonism like symptoms in rats. Issue 2 (June 2016)
- Main Title:
- Beneficial effect of antidepressants against rotenone induced Parkinsonism like symptoms in rats
- Authors:
- Sharma, Nidhika
Jamwal, Sumit
Kumar, Puneet - Abstract:
- Abstract: Parkinson's disease is a second most common age-related neurodegenerative disorder characterized by the loss of DA neurons of SNpc region of the midbrain. Neurotransmitter dysfunction is involved in the pathogenesis of PD. Antidepressants like venlafaxine and sertraline expected to improve Parkinsonism like symptoms by modulating the levels of various neurotransmitters. The neuroprotective role of antidepressants is well explored in various CNS disorders. Therefore, this study was designed to explore and compare the mechanistic role of different antidepressants (venlafaxine and sertraline) against rotenone induced Parkinsonism like symptoms in rats. Rats were administrated with rotenone (1.5 mg/kg/day; s.c.) daily for a period of 28 days. Venlafaxine (10 and 20 mg/kg; p.o.), sertraline (10 and 20 mg/kg; p.o.) and Levodopa combination with Carbidopa (10 mg/kg; p.o.) were administered daily starting from 7th day one hour prior to rotenone administration. Behavioral parameters (body weight, rotarod, grip strength, narrow beam walk and open field) were assessed on weekly basis. On 28th day, animals were sacrificed and striatum were isolated for biochemical (LPO, GSH and nitrite), neuroinflammatory (TNF-α, IL-1β and IL-6), neurochemical (DA, NE, 5-HT, GABA, Glutamate, DOPAC, HVA and 5-HIAA) and mitochondrial complex-I estimation. Rotenone administration significantly reduced body weight, motor coordination, oxidative defense, increased pro-inflammatory mediators andAbstract: Parkinson's disease is a second most common age-related neurodegenerative disorder characterized by the loss of DA neurons of SNpc region of the midbrain. Neurotransmitter dysfunction is involved in the pathogenesis of PD. Antidepressants like venlafaxine and sertraline expected to improve Parkinsonism like symptoms by modulating the levels of various neurotransmitters. The neuroprotective role of antidepressants is well explored in various CNS disorders. Therefore, this study was designed to explore and compare the mechanistic role of different antidepressants (venlafaxine and sertraline) against rotenone induced Parkinsonism like symptoms in rats. Rats were administrated with rotenone (1.5 mg/kg/day; s.c.) daily for a period of 28 days. Venlafaxine (10 and 20 mg/kg; p.o.), sertraline (10 and 20 mg/kg; p.o.) and Levodopa combination with Carbidopa (10 mg/kg; p.o.) were administered daily starting from 7th day one hour prior to rotenone administration. Behavioral parameters (body weight, rotarod, grip strength, narrow beam walk and open field) were assessed on weekly basis. On 28th day, animals were sacrificed and striatum were isolated for biochemical (LPO, GSH and nitrite), neuroinflammatory (TNF-α, IL-1β and IL-6), neurochemical (DA, NE, 5-HT, GABA, Glutamate, DOPAC, HVA and 5-HIAA) and mitochondrial complex-I estimation. Rotenone administration significantly reduced body weight, motor coordination, oxidative defense, increased pro-inflammatory mediators and decreased level of catecholamines. Pre-treatment with venlafaxine and sertraline significantly attenuated the alteration in behavioral, oxidative stress, neuroinflammatory, mitochondrial and catecholamines level in striatum. The study provides a hope that these drugs could be used as adjuvant therapy in the management and treatment of PD. … (more)
- Is Part Of:
- Pathophysiology. Volume 23:Issue 2(2016)
- Journal:
- Pathophysiology
- Issue:
- Volume 23:Issue 2(2016)
- Issue Display:
- Volume 23, Issue 2 (2016)
- Year:
- 2016
- Volume:
- 23
- Issue:
- 2
- Issue Sort Value:
- 2016-0023-0002-0000
- Page Start:
- 123
- Page End:
- 134
- Publication Date:
- 2016-06
- Subjects:
- 5-HIAA 5-hydroxyindoleacetic acid -- 5-HT 5-hydroxytryptamine -- BBB blood brain barrier -- BDNF brain-derived neurotrophic factor -- CMC carboxy-methyl-cellulose -- CNS Central nervous system -- Con control -- DA dopamine -- DAT dopamine transporter -- DOPAC 3, 4-dihydroxyphenylacetic acid -- EDTA ethylenediaminetetraacetic acid -- ELISA enzyme-linked immunosorbent assay -- GSH glutathione -- HPLC high-performance liquid chromatography -- HVA homovanillic acid -- IL-1β Iinterleukin-1β -- IL-6 interleukin-6 -- LPO lipid peroxidation -- MDA malondialdehyde -- NE nor-epinephrine -- NO nitric oxide -- PD Parkinson's disease -- ROS reactive oxygen species -- Rot rotenone -- rpm rotation per minute -- Ser sertraline -- SNPc substantia nigra pars compacta -- SNRI serotonin-nor epinephrine reuptake inhibitors -- SSRI selective serotonin re-uptake inhibitors -- TNF-α tumor necrosis factor-α
Parkinson's disease -- Sertraline -- Venlafaxine -- Basal ganglia -- Mitochondria -- Neurodegeneration -- Substantia nigra
Physiology, Pathological -- Periodicals
571.9 - Journal URLs:
- http://www.sciencedirect.com/science/journal/09284680 ↗
https://www.mdpi.com/journal/pathophysiology ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.pathophys.2016.03.002 ↗
- Languages:
- English
- ISSNs:
- 0928-4680
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6412.834000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 250.xml